LGALS1/Galectin 1 Protein

Catalog No. ABIN7321171

Recombinant LGALS1/Galectin 1 protein expressed in Escherichia coli (E. coli).

Quick Overview for LGALS1/Galectin 1 Protein (ABIN7321171)

Target: LGALS1/Galectin 1 (LGALS1) (Lectin, Galactoside-Binding, Soluble, 1 (LGALS1))

Protein Type: Recombinant

Origin: Rat

Source: Escherichia coli (E. coli)

Purity: > 95 % as determined by SDS-PAGE

Product Details

Purpose: Recombinant Rat Galectin-1/LGALS1 Protein

Sequence: Ala2-Glu135

Characteristics: A DNA sequence encoding the rat Galectin1 (P11762) (Ala2-Glu135) was expressed and purified.

Application Details

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Please refer to the printed manual for detailed information.

Buffer: Lyophilized from sterile PBS, pH 7.5

Storage: 4 °C,-20 °C,-80 °C

Storage Comment: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.

Target Details

Target: LGALS1/Galectin 1 (LGALS1) (Lectin, Galactoside-Binding, Soluble, 1 (LGALS1))

Alternative Name: Galectin-1/LGALS1

Background:

Background: Galectin-1 (Gal-1, GAL1), is a member of the galectins, a family of animal lectins ranging from Caenorhabditis elegans to humans, which is defined by their affinity for beta-galactosides and by significant sequence similarity in the carbohydrate-binding site. It is a homodimer with a subunit molecular mass of 14.5 kDa, which contains six cysteine residues per subunit. The cysteine residues should be in a free state in order to maintain a molecular structure that is capable of showing lectin activity. This endogenous lectin widely expressed at sites of inflammation and tumour growth, has been postulated as an attractive immunosuppressive agent to restore immune cell tolerance and homeostasis in autoimmune and inflammatory settings. On the other hand, galectin-1 contributes to different steps of tumour progression including cell adhesion, migration and tumour-immune escape, suggesting that blockade of galectin-1 might result in therapeutic benefits in cancer. Several potential glycoprotein ligands for galectin-1 have been identified, including lysosome-associated membrane glycoproteins and fibronectin, laminin, as well as T-cell glycoproteins CD43 and CD45. Evidence points to Gal-1 and its ligands as one of the master regulators of such immune responses as T-cell homeostasis and survival, T-cell immune disorders, inflammation and allergies as well as host-pathogen interactions.

Synonym: Galectin1,Lgals1

Molecular Weight: 14.9 kDa

UniProt: P11762

Pathways: Carbohydrate Homeostasis